Pennsylvania Medicaid does not cover Wegovy when it is prescribed for weight loss in adults. As of January 1, 2026, the state Department of Human Services ended coverage for every drug containing a GLP-1 receptor agonist when used to treat overweight or obesity in beneficiaries aged 21 and older. Wegovy is still covered, with prior authorization, when it is prescribed for an approved non-weight-loss indication such as reducing cardiovascular risk in patients with established heart disease. Coverage for patients under 21 is also preserved under federal law.
What Ended on January 1, 2026
Medical Assistance Bulletin MAB2025112403, issued November 24, 2025, terminated coverage of all GLP-1 medications prescribed for overweight or obesity in adults. The policy applies across fee-for-service Medicaid and every managed care organization operating in Pennsylvania, including UPMC, AmeriHealth Caritas, and Jefferson Health Plans. Federal law treats weight-loss drug coverage as optional for state Medicaid programs, and Pennsylvania chose to drop it.
There is no grandfathering. Adults who had been taking Wegovy, Zepbound, or a similar medication for weight loss lost that benefit at the start of the year. Every existing prior authorization for a GLP-1, even one written for a covered condition like diabetes, was invalidated as of December 31, 2025. A new prior authorization request had to be submitted with a start date of January 1, 2026, or later. Saxenda (liraglutide) was dropped from coverage entirely, for any indication.
About 70,000 Medicaid patients in the state had been prescribed a GLP-1 for some reason before the cutoff.
When Wegovy Is Still Covered
Wegovy remains a covered benefit under Pennsylvania Medicaid when it is prescribed to reduce the risk of heart attack, stroke, and cardiovascular death in adults who have established cardiovascular disease and are overweight or obese. This is Wegovy’s FDA-approved cardiovascular indication, and it is distinct from weight-loss treatment.
Approval for the cardiovascular indication requires all of the following:
- A prescription from, or written in consultation with, a specialist
- A BMI of at least 27
- Documentation of a qualifying cardiovascular event or condition, such as a prior heart attack, prior stroke, or peripheral arterial disease
- Use alongside optimized cardiovascular pharmacotherapy and lifestyle modifications
Approvals under this pathway last up to six months, after which the prescriber must seek reauthorization.
Other GLP-1 medications, including Ozempic, Mounjaro, and Trulicity, remain covered for their own approved non-weight-loss uses, all with prior authorization. Covered indications include type 2 diabetes (approvals up to 12 months, with preferred agents requiring a diabetes diagnosis or recent antidiabetic drug use and non-preferred agents requiring documented failure or intolerance of preferred options), moderate to severe obstructive sleep apnea in patients with obesity, and metabolic dysfunction-associated steatohepatitis (MASH).
A physician reviewer can approve a prior authorization request that doesn’t meet the standard clinical criteria if, in the reviewer’s professional judgment, the medication is medically necessary for that patient.
Coverage for Patients Under 21
The weight-loss exclusion does not apply to children and young adults under 21. Federal law requires Medicaid to cover all medically necessary treatments for this age group through the Early and Periodic Screening, Diagnosis and Treatment benefit, known as EPSDT. A Medicaid plan cannot issue a blanket denial for a GLP-1 prescribed for obesity in someone under 21. The plan has to evaluate medical necessity for the individual patient and explain any denial.
Patients under 21 still needed a new prior authorization submitted before their old one expired at the end of 2025. If a plan denies coverage for a minor on the grounds that weight-loss treatment isn’t covered, the Pennsylvania Health Law Project and other advocacy groups advise appealing. Filing an appeal within 15 days of the denial notice generally allows coverage to continue while the appeal is decided.
Weight-Loss Treatments Still Covered
The state did not eliminate all obesity treatment coverage for adults. Non-GLP-1 weight-loss medications on the Statewide Preferred Drug List remain available without prior authorization, subject to quantity and daily dose limits. The bulletin identified phentermine capsules and phentermine tablets as preferred agents that continue to be covered. Non-preferred obesity treatment agents that don’t contain a GLP-1 are also still covered but require prior authorization, including documentation that preferred alternatives failed or couldn’t be tolerated.
Bariatric surgery remains a covered benefit under Pennsylvania Medicaid managed care plans, with prior authorization. Multiple MCOs, including UnitedHealthcare Community Plan, Pennsylvania Health and Wellness, and Highmark Wholecare, cover procedures such as gastric bypass, sleeve gastrectomy, and adjustable gastric banding for patients who meet BMI thresholds. Adults with a BMI of 40 or above generally qualify, as do those with a BMI of 35 or above who have at least one obesity-related comorbidity such as type 2 diabetes, cardiovascular disease, or obstructive sleep apnea. Most plans also require a documented history of failed physician-supervised weight-loss efforts and a psychological evaluation before surgery.
Behavioral counseling and nutritional consultation for adult obesity are generally not covered as standalone Medicaid services, though some managed care plans offer supplemental wellness programs. Highmark Wholecare provides a healthy weight management program that includes health coaching, nutrition support, and care coordination at no cost to members. These programs vary by plan.
If Your Prescription Is Denied
If you were taking a GLP-1 for weight loss and also have a qualifying medical condition, such as type 2 diabetes, established cardiovascular disease, obstructive sleep apnea, or MASH, the clearest path to continued coverage is to ask your doctor to submit a new prior authorization for that non-weight-loss indication. Managed care organizations follow the same prior authorization guidelines set by the Department of Human Services, though each MCO has its own submission process.
If you receive a denial, you can appeal through your Medicaid HealthChoices managed care plan. Filing the appeal within 15 days of the denial date may keep your coverage in place during the appeals process. The Pennsylvania Health Law Project has published guidance advising patients to pursue appeals aggressively, particularly for individuals under 21 whose EPSDT protections remain in effect.
Patients who are dually eligible for both Medicare and Medicaid may be able to get coverage through their Medicare plan for conditions like diabetes or sleep apnea.
What May Change
In November 2025, the Trump administration announced agreements with Novo Nordisk and Eli Lilly to set the Medicare and Medicaid price for Ozempic, Wegovy, Mounjaro, and Zepbound at $245 per month, down from list prices that ranged from roughly $1,000 to $1,350. Both companies agreed to extend most-favored-nation pricing to state Medicaid programs, but states have to opt in.
CMS launched the BALANCE model in December 2025, a voluntary five-year program under which the agency negotiates GLP-1 prices with manufacturers on behalf of participating state Medicaid programs and Medicare Part D plans. States had until July 31, 2026, to apply, with coverage rolling out from May 2026 through January 2027. Whether Pennsylvania will participate has not been publicly announced. For dually eligible patients, Medicare is set to begin covering Wegovy and Zepbound for obesity-related indications through the BALANCE pilot as early as mid-2026.
State Representatives Arvind Venkat (D-Allegheny) and Bryan Cutler (R) introduced HB 1470 in May 2025, proposing a subscription payment model for GLP-1 medications under which Pennsylvania would pay a set amount per treatment up to a cap, with the manufacturer providing additional treatments at no extra cost afterward. The bill was referred to the House Committee on Human Services on May 15, 2025. As of late June 2026, it has not received a committee hearing or a vote.